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The original publication of this article \[[@CR1]\] contained few erroneous paragraphs and errors in Table 1 and Table 2. The first four paragraphs are in the 'Results' section while the last four paragraphs are in the 'Discussion' section. The errors in Table 1 involve the number of isolates tested for pyrazinamide and pyrazinamide susceptible isolates, ethambutol-susceptible isolates with a mutation and number of resistant isolates with a mutation for streptomycin. The error in Table 2 involves wrong codon number for a mutation in isolate KM17-01 in Cluster XII for *gidB* gene. The updated informations have been indicated in **bold** and also refer corrected Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}.Table 1Phenotypic resistance by MGIT 960 system to anti-TB drugs among 93 multidrug-resistant *M. tuberculosis* isolates and number of susceptible and resistant isolates with mutations in target genes for each drugAnti-tuberculosis drugNo. of isolates testedNo. of susceptible isolatesNo. of susceptible isolates with mutation^a^No. of resistant isolatesNo. (%) of resistant isolates with mutation^a^Rifampicin93009393 (100)Isoniazid93009392 (98.9)Pyrazinamide**4610**03630 (83.3)Ethambutol9352**39**^b^4138 (92.7)Streptomycin9334059**51 (86.4)**^a^Resistance conferring mutations were detected in *rpoB* for rifampicin, *katG* + *inhA* for isoniazid, *pncA* for pyrazinamide, *embB* for ethambutol, and *rpsL* + rrs for streptomycin^b^*M. tuberculosis* isolates with *embB* mutations usually confer low level of resistance to ethambutol which are often missed by the MGIT 960 system \[23, 28\]Table 2Detailed clinical, demographic and molecular characteristics of 42 *M. tuberculosis* isolates in 16 (Cluster I to Cluster XVI) clustersCluster no.Clinica specimenIsolate no.Year of isolationPatient's nationalitySpoligotyping dataGenetic alteration detected inSITMtb family*rpoBkatGinhApncAembBrpsLrrsgidBrpsA*ISputumKM06-1532006Indian255BeijingTCG456TTGACG315ACCWTWTATG306GTGAAG43AGGWTN. D.N. D.CSFKM09-222009Indian255BeijingTCG456TTGACG315ACCWTWTATG306GTGAAG43AGGWTN. D.N. D.SputumKM13-372013Indian1BeijingTCG456TTGACG315ACCWTWTATG306GTGAAG43AGGWTN. D.N. D.FNAKM16-062016Nepalese1BeijingTCG456TTGACG315ACCWTWTATG306GTGAAG43AGGWTN. D.N. D.FNAKM17-032017Indian1BeijingTCG456TTGACG315ACCWTWTATG306GTGAAG43AGGWTN. D.N. D.IISputumKM14-582014Nepalese1BeijingTCG456TTGACG315ACCWTGTG139GCGATG306GTGAAG43AGGWTGAA92GAC + *GCA205GCGCGA212CGC*SputumKM14-692014Indian1BeijingTCG456TTGACG315ACCWTGTG139GCGATG306GTGAAG43AGGWT*GCA205GCG*WT[IIISputumKM08-5012008Kuwaiti1BeijingTCG456TTGACG315ACCWTGGT139GTTATG306GTGAAG43AGGWTGAA92GAC + ]{.ul}*[GCA205GCG]{.ul}[CGA212CGC]{.ul}*[SputumKM08-5022008Kuwaiti1BeijingTCG456TTGACG315ACCWTGGT139GTTATG306GTGAAG43AGGWTGAA92GAC + ]{.ul}*[GCA205GCG]{.ul}[CGA212CGC]{.ul}*[SputumKM09-2072009Indian1BeijingTCG456TTGACG315ACCWTGGT139GTTATG306GTGAAG43AGGWTGAA92GAC + ]{.ul}*[GCA205GCG]{.ul}[CGA212CGC]{.ul}*IVSputumKM12-052012Ethiopian21CAS1-KiliTCG456TTGACG315ACCWTIns193A (FS) + *TCC65TCT*ATG306GTGAAG88AGGWTN. D.N. D.SputumKM12-172012Ethiopian1144T1TCG456TTGACG315ACCWTIns193A (FS) + *TCC65TCT*ATG306GTGAAG88AGGWTN. D.N. D.SputumKM15-082015Ethiopian21CAS1-KiliTCG456TTGACG315ACCWTIns193A (FS) + *TCC65TCT*ATG306GTGAAG88AGGWTN. D.N. D.VSputumKM07-3332007IndonesianOrphanN. A.TCG456TTGACG315ACCWTWTWTWTWTN. D.N. D.SputumKM10-232010Indian355EAI3-INDTCG456TTGACG315ACCWTWTWTWTWTN. D.N. D.VISputumKM07-2932007Filipino194LAM2TCG456TTGACG315ACCWTWTCAG497CGGWTWTN. D.N. D.SputumKM12-012012Filipino25CAS1-DelhiTCG456TTGACG315ACCWTWTCAG497CGGWTWTN. D.N. D.VIISputumKM09-2022009Ethiopian47H1GTC176TTCACG315ACCWTWTWTWTWTN. D.N. D.SputumKM15-172015Indian47H1GTC176TTCACG315ACCWTWTWTWTWTN. D.N. D.[VIIISputumKM14-672014Ethiopian149T3-ETHTCG456TTGACG315ACCWT− 11 A/GATG306ATCWTWTGGT69GATWTSputumKM15-212015Ethiopian149T3-ETHTCG456TTGACG315ACCWT− 11 A/GATG306ATCWTWTGGT69GATWT]{.ul}IXSputumKM07-2832007Indian26CAS1-DelhiTCG456TTGACG315ACCWT*TCC65TCT*ATG306ATAWTWTN. D.N. D.SputumKM14-682014IndianOrphanN. A.TCG456TTGACG315ACCWT*TCC65TCT*ATG306ATAWTWTN. D.N. D.SputumKM17-202017Kuwaiti1BeijingTCG456TTGACG315ACCWT− 11 A/GCAG497CGGAAG43AGGWTGAA92GAC + *GCA205GCG*WTXSputumKM17-222017Kuwaiti1BeijingTCG456TTGACG315ACCWT− 11 A/GCAG497CGGAAG43AGGWTGAA92GAC + *GCA205GCGCGA212CGC*SputumKM17-732017Indian1BeijingTCG456TTGACG315ACCWT− 11 A/GCAG497CGGAAG43AGGWTGAA92GAC + *GCA205GCGCGA212CGC*[PusKM11-5032011Kuwaiti1BeijingTCG456TTGACG315ACCWT− 11 A/GGGC406GACAAG43AGGWTGAA92GAC + GCA205GCG]{.ul}*[CGA212CGC]{.ul}*[SputumKM14-562014Kuwaiti1BeijingTCG456TTGACG315ACCWT− 11 A/GGGC406GACAAG43AGGWTGAA92GAC + GCA205GCG]{.ul}*[CGA212CGC]{.ul}*[XISputumKM15-132015Kuwaiti1BeijingTCG456TTGACG315ACCWT− 11 A/GGGC406GACAAG43AGGWTGAA92GAC + GCA205GCG]{.ul}*[CGA212CGC]{.ul}*[SputumKM15-262015Kuwaiti1BeijingTCG456TTGACG315ACCWT− 11 A/GGGC406GACAAG43AGGWTGAA92GAC + ]{.ul}*[GCA205GCG]{.ul}[CGA212CGC]{.ul}*[SputumKM17-022015Kuwaiti1BeijingTCG456TTGACG315ACCWT− 11 A/GGGC406GACAAG43AGGWTGAA92GAC + ]{.ul}*[GCA205GCG]{.ul}[CGA212CGC]{.ul}*[SputumKM17-692017Kuwaiti1BeijingTCG456TTGACG315ACCWT− 11 A/GGGC406GACAAG43AGGWTGAA92GAC + ]{.ul}*[GCA205GCG]{.ul}[CGA212CGC]{.ul}*XIISputumKM16-322016Egyptian19EAI2-ManilaCAC451TACACG315ACC− 15 C/TGAA37AAA*CTG355CTA* + GAG378GCGWTWT*GTG110GTT* + *GCA205GCG*WTSputumKM17-012017Filipino19EAI2-ManilaCAC451TACACG315ACC− 15 C/TGAA37AAA*CTG355CTA* + GAG378GCGWTWT**CTC59TTC **+ *GTG110GTT* + *GCA205GCG*WTXIIIPusKM07-2972007IndianOrphanN. A.CAC451GACWT− 15 C/T*TCC65TCG* + Ins 453T (FS)ATG306CTGWTWTN. D.N. D.FNAKM11-5022015Indian3361T1CAC451GACWT− 15 C/T*TCC65TCG* + Ins 453T (FS)ATG306CTGWTWTN. D.N. D.XIVSputumKM06-482006Egyptian53T1TCG456TTGWT− 15 C/TWTWTWTWTN. D.N. D.TissueKM06-2772006Filipino19EAI2-ManilaTCG456TTGWT− 15 C/TWTWTWTWTN. D.N. D.[XVSputumKM16-332016Indian8EAI3/EAI5CAC451TACACG315ACCWTCTG35CCGATG306GTG + GAG378GCGAAG43AGGWT]{.ul}*[GTG110GTT]{.ul}*[ + ]{.ul}*[GCA205GCG]{.ul}*[WTSputumKM17-062017Filipino8EAI3/EAI5CAC451TACACG315ACCWTCTG35CCGATG306GTG + GAG378GCGAAG43AGGWT]{.ul}*[GTG110GTT]{.ul}*[ + ]{.ul}*[GCA205GCG]{.ul}*[WTXVISputumKM07-2312007IndianOrphan]{.ul}^[a]{.ul}^[CAS1-DelhiATG440ATA + GAC441TACACG315ACCWT]{.ul}*[TCC65TCT]{.ul}*[GGC406TGCWTWT]{.ul}*[GCA205GCG]{.ul}*[ + Del 350G (FS)WTSputumKM07-2522007SyrianOrphan]{.ul}^[a]{.ul}^[CAS1-DelhiATG440ATA + GAC441TACACG315ACCWT]{.ul}*[TCC65TCT]{.ul}*[GGC406TGCWTWT]{.ul}*[GCA205GCG]{.ul}*[ + Del 350G (FS)WT]{.ul}Clusters containing MDR-TB strains with identical patterns and isolated within a period of nearly 2 years are shown as underlined. Synonymous mutations are italicizedN. A., not applicable; N. D., not done; CSF, cerebrospinal fluid; FNA, fine needle aspirate; SIT, shared international type; Mtb family, *M. tuberculosis* family; WT, wild-type sequence; Ins, insertion mutation; (FS), frame shift mutation, fine needle aspirate^a^Both isolates displayed identical spoligotyping pattern

**Incorrect:** Although all 93 MDR-TB isolates were tested for susceptibility to pyrazinamide, only 47 isolates yielded interpretable results; 11 isolates were susceptible and 36 were resistant to this drug including 15 isolates that were resistant to all five drugs. The remaining 46 MDR-TB strains failed to grow at the reduced pH in the absence of the drug.

**Correct:** Although all 93 MDR-TB isolates were tested for susceptibility to pyrazinamide, only **46 isolates** yielded interpretable results; **10 isolates** were susceptible and 36 were resistant to this drug including 15 isolates that were resistant to all five drugs. The remaining **47 MDR-TB strains** failed to grow at the reduced pH in the absence of the drug.

**Incorrect:** The proportion of MDR-TB isolates exhibiting resistance conferring mutations in target genes varied for different anti-TB drugs, being highest for rifampicin and lowest for streptomycin (Table 1).

**Correct:** The proportion of MDR-TB isolates exhibiting resistance conferring mutations in target genes varied for different anti-TB drugs, being highest for rifampicin and lowest for streptomycin **among SIRE drugs** (Table 1).

**Incorrect:** PCR-sequencing of *pncA* identified mutations in 30 of 36 MDR-TB strains phenotypically resistant to pyrazinamide and 23 of 46 isolates for which phenotypic DST data for pyrazinamide was not available while all 11 isolates phenotypically susceptible to pyrazinamide contained wild-type sequence for *pncA*.

**Correct:** PCR-sequencing of *pncA* identified mutations in 30 of 36 MDR-TB strains phenotypically resistant to pyrazinamide and 23 of **47** isolates for which phenotypic DST data for pyrazinamide was not available while all **10** isolates phenotypically susceptible to pyrazinamide contained wild-type sequence for *pncA*.

**Incorrect:** Fifty isolates contained mutations at *embB306* (M306V, n = 28; M306I, n = 19 and M306L, n = 3), 15 isolates contained a mutated *embB406* (G406D, n = 8; G406A, n = 4; G406C, n = 2 and G406S, n = 1), 10 isolates contained a mutated *embB497* (Q497R, n = 6; Q497K, n = 3 and Q497H, n = 1) and one isolate contained a mutation (Y319S) at *embB319*.

**Correct:** Fifty isolates contained mutations at *embB306* (M306V, n = 28; M306I, n = 19 and M306L, n = 3), **16** isolates contained a mutated *embB406* (G406D, n = 8; G406A, **n = 5**; G406C, n = 2 and G406S, n = 1), 10 isolates contained a mutated *embB497* (Q497R, n = 6; Q497K, n = 3 and Q497H, n = 1) and one isolate contained a mutation (Y319S) at *embB319*.

**Incorrect:** Forty-nine of 59 MDR-TB strains additionally resistant to streptomycin contained a mutation in the target genes analysed (Table 1), many of which have been described previously \[23, 28\]. These included 44 isolates with a mutation in *rpsL* (K43R, n = 33; K43T, n = 1; K88R, n = 5; K88T, n = 4; K88M, n = 1), four isolates with a mutation in *rrs* 500 or 900 region (A514C, n = 1; C517T, n = 1; G878A, n = 1 and A906G, n = 1) and one isolate with *rpsL* K88R + *rrs* C602A double mutation.

**Correct: Fifty-one** of 59 MDR-TB strains additionally resistant to streptomycin contained a mutation in the target genes analysed (Table 1), many of which have been described previously \[23, 28\]. These included 44 isolates with a mutation in *rpsL* (K43R, n = 33; K43T, n = 1; K88R, n = 5; K88T, n = 4; K88M, n = 1), four isolates with a mutation in *rrs* 500 or 900 region (A514C, n = 1; C517T, n = 1; G878A, n = 1 and A906G, n = 1) and **three isolates with double mutation in*rpsL*and*rrs*genes (*rpsL*K43R + *rrs*C527T, n = 1;*rpsL*K88T + *rrs*C517T, n = 1;*rpsL*K88R + *rrs*C602A, n = 1)**.

**Incorrect:** Resistance conferring mutations in *rpsL* and/or *rrs* gene were detected in majority (49 of 59, 83%) of streptomycin-resistant but not in any streptomycin-susceptible MDR-TB strain while mutations in *embB* gene were detected in both ethambutol-resistant and -susceptible MDR-TB strains, as described in our previous studies \[23, 28\].

**Correct:** Resistance conferring mutations in *rpsL* and/or *rrs* gene were detected in majority **(51 of 59, 86.4%)** of streptomycin-resistant but not in any streptomycin-susceptible MDR-TB strain while mutations in *embB* gene were detected in both ethambutol-resistant and -susceptible MDR-TB strains, as described in our previous studies \[23, 28\].

**Incorrect:** Phenotypic DST results for pyrazinamide were available for only 47 of 93 MDR-TB strains while the remaining 46 isolates failed to grow at lower pH. No *pncA* mutation was detected in 50 pansusceptible strains. Analysis of 93 MDR-TB strains showed that 30 of 36 MDR-TB strains phenotypically resistant to pyrazinamide and 23 of 46 isolates for which DST data for pyrazinamide was not available contained a mutation in *pncA* while all 11 MDR-TB strains phenotypically susceptible to pyrazinamide contained wild-type sequence for *pncA*.

**Correct:** Phenotypic DST results for pyrazinamide were available for only **46** of 93 MDR-TB strains while the remaining **47** isolates failed to grow at lower pH. No *pncA* mutation was detected in 50 pansusceptible strains. Analysis of 93 MDR-TB strains showed that 30 of 36 MDR-TB strains phenotypically resistant to pyrazinamide and 23 of **47** isolates for which DST data for pyrazinamide was not available contained a mutation in *pncA* while all **10** MDR-TB strains phenotypically susceptible to pyrazinamide contained wild-type sequence for *pncA*.

**Incorrect:** The two isolates in Cluster XII were also very closely related, with the second isolate (KM17-01) displaying an additional mutation (L95F) in *gidB* which is considered as a hot-spot for mutations in the *M. tuberculosis* genome \[21, 57\].

**Correct:** The two isolates in Cluster XII were also very closely related, with the second isolate (KM17-01) (Table [2](#Tab2){ref-type="table"}) displaying an additional mutation **(L59F)** in *gidB* which is considered as a hot-spot for mutations in the *M. tuberculosis* genome \[21, 57\].
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